Bayer

News

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome.

News

Bayer has started a phase 3 trial of its Mirena contraceptive in an endometrial disorder, with no treatments, that can lead to cancer.

News

Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.

News

Bayer joins Boehringer with FDA approval for a second-line, oral therapy for HER2-positive lung cancer, setting up a marketing battle in the US.

News

Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.

News

Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead.